Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

liver, lung and lymph node metastases. The duration of response, independently reviewed, ranged from 7.1 weeks to 30.0 weeks. The median time to progression in the treated population was 5.9 weeks. The adverse events were manageable, predictable and consistent with those seen in the Phase I trials of ispinesib. The most common grade 3/4 adverse events observed were neutropenia, febrile neutropenia and neutropenic sepsis.

In addition, GSK has sponsored three dose-escalating Phase Ib clinical trials. Each of these clinical trials was designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib in combination with a leading anti-cancer therapeutic, one in combination with carboplatin, the second in combination with capecitabine, and the third in combination with docetaxel. The clinical trial evaluating ispinesib in combination with capecitabine is closed to enrollment. Final data from this trial are expected in 2007.

Under a November 2006 amendment to its collaboration and license agreement with GSK, Cytokinetics has assumed responsibility for the costs and activities associated with the continued development of the KSP inhibitors, ispinesib and SB-743921, subject to GSK s option to resume responsibility for some or all development and commercialization activities associated with each of these novel drug candidates. Cytokinetics plans to conduct, at its expense, a focused development program for ispinesib in breast cancer specifically designed to supplement the broad series of Phase I and Phase II clinical trials sponsored by GSK that have demonstrated clinical activity in the treatment of patients with metastatic breast cancer and that have shown an acceptable tolerability profile for ispinesib in combination with standard chemotherapeutics.

The NCI has sponsored six additional Phase II clinical trials, evaluating the potential efficacy of ispinesib in an array of different tumor types. Enrollment has been closed for
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ), a ... proprietary products to treat voiding dysfunctions, today reported financial ... 2014.  Global revenue for the Company,s Urgent ... a new quarterly revenue record, as compared to $3.9 ...
(Date:1/22/2015)... , Jan. 22, 2015  Profil Institute for Clinical Research, ... and obesity, announced today a new textbook,  Translational Research ... by Springer, a leading global scientific publisher. ... illustrate techniques for use in early phase clinical studies ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... N.J., March 29, 2011 Konica Minolta Sensing Americas, ... of color, light and shape, announces the launch of ... to the pharmaceutical industry at the 2011 Interphex show ... Convention Center. (Photo: http://photos.prnewswire.com/prnh/20100714/NY35146 ) ...
... 2011 SCOLR Pharma, Inc. (OTC Bulletin Board: ... ended December 31, 2010, and also provided updates on a ... Under the Company,s current operating plan, its cash ... quarter of 2011, provided that it may experience additional constraints ...
Cached Medicine Technology:Konica Minolta Sensing Announces CM-5 Spectrophotometer to Pharmaceutical Industry at Interphex 2011 2Konica Minolta Sensing Announces CM-5 Spectrophotometer to Pharmaceutical Industry at Interphex 2011 3SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs 2SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs 3SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs 4SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs 5SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs 6SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs 7
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television host, ... 32nd Annual Miami Breast Cancer Conference planned and ... , shares that “a fast-growing, virulent” cancer in her ... not followed up her clean mammogram with an ultrasound. ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... Bone Health with Daughters WASHINGTON, May 1 Of all ... their loved ones, one of the most important is the ... health and osteoporosis. The National Osteoporosis Foundation (NOF) is sponsoring ... theme for Osteoporosis Awareness and Prevention this May to help ...
... influenza A (swine flu) spreads, keeping hands clean is ... infection and illness. "Frequent handwashing is probably the single ... protect yourself and your family," according to Dr. Judy ... viruses, of which swine flu is one, are fragile ...
... Dr. Candace Pert will join Chopra Center co-founders, Deepak Chopra, M.D. ... that integrates the ancient healing system of Ayurveda with the latest ... ... Carlsbad, CA (PRWEB) May 1, 2009 -- Mind-body healing pioneer, best-selling ...
... BEIJING, May 1 IBM (NYSE: IBM ... Industry Solution Lab in Beijing, where IBM will work ... "smarter" as the Chinese government enacts widespread healthcare reform. ... at IBM,s new Healthcare Industry Solution Lab -- which ...
... Urges Shareholders to Support the Board,s Strategy and Vote the ... May 1 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... shareholders in connection with the Company,s Annual Meeting of Stockholders ... to vote FOR Amylin,s Directors on the BLUE proxy card ...
... *Swine Flu Outbreak Highlights Influenza Virus Research at Drexel ... University has demonstrated the importance of natural killer, ... These findings may help us understand how the ... emergent swine flu.While no studies have been conducted on ...
Cached Medicine News:Health News:Family History is Key Risk Factor in Developing Osteoporosis 2Health News:Family History is Key Risk Factor in Developing Osteoporosis 3Health News:American Society for Microbiology Emphasizes Hand Hygiene as Flu Protective Measure 2Health News:World-Renowned Neuroscientist Dr. Candace Pert will be Featured Speaker at the Chopra Center's Signature Mind-Body Healing Workshop in San Diego 2Health News:World-Renowned Neuroscientist Dr. Candace Pert will be Featured Speaker at the Chopra Center's Signature Mind-Body Healing Workshop in San Diego 3Health News:IBM Announces New Healthcare Industry Solutions Lab in China 2Health News:IBM Announces New Healthcare Industry Solutions Lab in China 3Health News:IBM Announces New Healthcare Industry Solutions Lab in China 4Health News:Amylin Sends Letter to Shareholders 2Health News:Amylin Sends Letter to Shareholders 3Health News:Amylin Sends Letter to Shareholders 4Health News:Amylin Sends Letter to Shareholders 5Health News:Amylin Sends Letter to Shareholders 6Health News:Natural Killer Cells May Help Protect Against New Strains of Influenza Virus 2Health News:Natural Killer Cells May Help Protect Against New Strains of Influenza Virus 3
... unique system uses prolene as thread-guide reducing ... The hollow Ritleng Probe is inserted into ... thread-guide is fed through it. The probe ... to pull the silicone tubing in place. ...
Recommended to insert plug portion of all monocanalicular intubation systems into punctum....
For proper plug sizing....
To prevent retraction of the conjunctival cul-de-sacs without touching the cornea....
Medicine Products: